5th International Conference on Cardiovascular Medicine and Cardiac Surgery

Feb 16-17, 2022


Rome, Italy

 Welcome Message

We cordially welcome the expertise of Cardiology and Healthcare to the event Cardiovascular Medicine and Cardiac Surgery during Feb 16-17,2022 in Rome, Italy

About Conference:

The International Conference on Cardiovascular Medicine and Cardiac Surgery will be held in Rome, Italy on February 16-17, 2022.

The 5t International Cardiovascular Medicine and Cardiac Surgery Conference is a top educational Heart Congress in the field of Cardiac Surgery and Cardiac Medicine that rotates between continents and is produced in partnership with international   organizations.

The theme of this International Conference on Cardiovascular Medicine and Cardiac Surgery, which will be place in Rome, Italy on February 16-17, is “Another Step Towards Cardiovascular Medicine and Cardiac Surgery Advancement” The International Conference on Cardiovascular Medicine and Cardiac Surgery is aimed at the global cardiology, cardio medicine, cardiac surgery, and cardiovascular communities, as well as other healthcare professionals interested in interdisciplinary heart care, allowing specialists from all over the world to share their perspectives on a wide range of problems impacting the heart and those suffering from heart disease.

Why to Attend?

  • Cardiovascular Medicine 2022   is one of the world's leading Scientific conferences to bring together globally renowned cardiology healthcare practitioners, scientists, public health experts, academics, academic scientists, industry researchers, and scholars to share ideas. To get a competitive advantage, be the first to promote your research, innovation, and brand. Meet your target market and educate them about your products and services.
  • To Meet Experts and Learn in a New Environment
  • New Strategies & Techniques
  • Certification
  • Global Collaboration
  • Establish a New Customer Base

Target Audience:

Leading world Doctors,




Associate Professors,

Registered Nurses,

Research Fellows,


Instructors and many more from leading universities, companies and medical research institutions, hospitals sharing their novel researches in the arena of Cardiology & Medicine.


Related Conference:

Cardiovascular Conferences | Heart Conferences | Cardiac Surgery Conferences | Cardiovascular 2021 | Cardiovascular Disease Conferences | Cardiovascular Physiology Conferences | Hypertension Conferences | Coronary Artery Diseases Conferences | Stroke Conferences | Heart Failure Conferences | Heart Disease Conferences | Rheumatic Heart Disease Conferences | Cardiomyopathy Conferences | Arrhythmia Conferences | Myocarditis Conferences | Cardiology Conferences

Related Societies:

USA: Brazilian Cardiology Society | THI Cardiac Society | Brazilian Society of Hypertension | Canadian Heart Rhythm Society | American Association for Thoracic Surgery | American Association of Heart Failure Nurses

Europe: British Association for Cardiovascular Prevention and Rehabilitation (BACPR) | British Association for Nursing in Cardiovascular Care (BANCC) | British Cardiovascular Intervention Society | Moldavian Society of Cardiology | Maltese Cardiac Society | Montenegro Society of Cardiology

Asia-Pacific: Asian Pacific Society of Cardiology | Asian Pacific Society of Cardiology | Asian Society for Cardiovascular and Thoracic Surgery | Japanese Heart Failure Society | Korean Society of Interventional Cardiology | Japanese Society of Pediatric Interventional Cardiology Session                                                    


The global cardiac surgery market is expected to reach $14.2 billion in 2021, with the market for cerebral embolic protection devices expected to develop at the quickest rate. Despite COVID19, the global market is predicted to grow over the next few years, surpassing $20.4 billion by 2027. The drive toward minimalism is a prominent trend in the global market for cardiac surgery devices. Invasive techniques that  increase patient health outcomes while also simplifying the operation. TAVI (transcatheter aortic valve implantation) and TMR (transcatheter mitral valve repair) are two examples of such procedures (TMVR). Both market segments are set to grow substantially, with new competitors entering the markets with new products to capture the growing demand The growing demography will boost market expansion. Increased demand from a growing patient population will drive market expansion. Throughout the investigation, significant market factors such as the ageing population and improved access to healthcare in emerging regions are examined.

Interventional and viscus devices are available on the global pharma market. By 2020, the global interventional pharmaceuticals devices market is anticipated to reach $25.16 billion. The Asia Pacific market, on the other hand, is expected to reach a peak of $6.4 billion by 2022, rising at a profit-making pace over the projected period. The global market for vas surgical devices used in the operating room is worth billions of dollars.

So drugs conferences area unit progressing to be an honest success these days as a result of the attention for the treatment of vas diseases is unbelievably necessary among the people and everybody will come to understand relating to the new researches occurring and inventions inside the sector of medication.


Prof Josef VESELKA
chief of Department of Cardiology
Department of Cardiology in Motol University Hospital


Prof. Josef Veselka, MD, PhD attended medical school at Charles University, Prague, Czech Republic and graduated in 1989. He is a chief of Department of Cardiology in Motol University Hospital, which is a largest Czech hospital. His main area of expertise and interest are cardiomyopathies and interventional cardiology, and he is one of the pioneers in the field of structural and coronary interventions. He has published more than 300 scientific papers, edited 6 monographs and textbooks, and is a member of several editorial boards of medical journals.

Researches :

  • His main area of expertise and interest are cardiomyopathies and interventional cardiology, and he is one of the pioneers in the field of structural and coronary interventions.
Avraham Lorber
president of PI-Harvest,


Prof. Avraham Lorber has earned his MD degree at the Tel Aviv University and his post graduate studies in Paediatric Cardiology in London. He completed his boards in Paediatrics, Cardiology and Paediatric Cardiology and served as Head of Congenital Heart Disease at the Rambam Medical Center and Prof. In Cardiology, the Faculty of Medicine – Technion. He is the president of PI-Harvest, Israel which is a R&D company for innovative medical technologies He has published more than 150 papers in peer-review journals in Congenital and Structural Pediatric and GUCH patients and was involved in clinical and basic research for genetic lethal arrhythmias.

Researches :

  • • Trans-catheter closure of the Atrial Septal Defect in elderly patients; a rewarding controversy. • Trans-catheter closure of the Patent Foramen Ovale to prevent recurrent CVA/TIA in patients with "cryptogenic stroke". • Hemodynamic variations after trans-catheter closure of atrial septal defects in various age groups. • Polymorphic Catecholaminergic Ventricular Tachycardia – an Autosomal Recessive Disease: processing of electrocardiographic data. • The familial forms of atrial septal defect and associated congenital phenotypic expressions. • Special innovative and unique achievements; Adaptive solutions for rare cardiovascular conditions
Hind Lal
Associate Professor of Medicine
The University of Alabama at Birmingham Birmingham


I am a tenured full-time faculty (Associate Professor of Medicine) at The University of Alabama at Birmingham (UAB). As a primary investigator in the Division of Cardiovascular Disease at UAB, I supervise basic and translational research activities of multiple trainee scientists at all levels, this includes postdoctoral Fellows, graduate, undergraduate, and medical students. The overall research theme of my lab is to understand the proteins and signaling pathways that regulate cardiac function and dysfunction. The findings from these investigations are expected to develop novel approaches, diagnostics and therapies to improve the prevention and treatment of HF and other cardiovascular complications. My research program is supported by research grants from the NIH and AHA. I am very active

Researches :

  • Cell Signaling Interventional Cardiology Cardiac Imaging Echocardiography Heart Failure Phosphorylation Cardiology Myocardial Infarction Cardiac Function Signaling
Founder and CEO
the cardiovascular lipid club journal meeting Dominican Republic


Dr Maxima Mendez Castillo, internist cardiologist, Master in lipids, graduated from the Autonomous University of Santo Domingo (UASD) in the Dominican Republic, as well as training in critical post-surgical cardiovascular care and coronary care at the National Institute of Cardiology Ignacio Chavez in Mexico. Currently assistant physician of the non-invasive cardiology department of the cardiovascular center Cedimat in the Dominican Republic. Has participated in multiple national and international conferences, as well as several courses and symposiums on cardiovascular medical updating and a diploma in strategic health management.